Jylamvo

Be fully familiar with this drug's toxicity before use. Obtain baseline and periodically monitor CBCs with differential, platelet counts, chest X-ray, and hepatic, renal and pulmonary function. Permanently discontinue if anaphylaxis or other severe hypersensitivity, or severe dermatologic reactions occur. Discontinue if lymphoproliferative disease occurs. Withhold, reduce dose, or discontinue if myelosuppression occurs. Withhold or discontinue if severe gastrointestinal toxicity, pulmonary toxicity, severe renal toxicity, or neurotoxicity occur. Peptic ulcer disease. Ulcerative colitis. Increased risk for hepatotoxicity with alcoholism or receiving total cumulative dose (≥1.5g); withhold or discontinue if occurs. Increased risk for serious infections (eg, bacterial, fungal, viral) including opportunistic infections; monitor during and after treatment; withhold or discontinue if occur. Folate deficiency. Ascites, pleural effusions: evacuate fluid, monitor for toxicity and reduce dose or discontinue if needed. Hepatic or renal impairment: monitor closely and reduce dose or discontinue as appropriate. Update immunizations according to current guidelines prior to initiation. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Be fully familiar with this drug's toxicity before use. Obtain baseline and periodically monitor CBCs with differential, platelet counts, chest X-ray, and hepatic, renal and pulmonary function. Permanently discontinue if anaphylaxis or other severe hypersensitivity, or severe dermatologic reactions occur. Discontinue if lymphoproliferative disease occurs. Withhold, reduce dose, or discontinue if myelosuppression occurs. Withhold or discontinue if severe gastrointestinal toxicity, pulmonary toxicity, severe renal toxicity, or neurotoxicity occur. Peptic ulcer disease. Ulcerative colitis. Increased risk for hepatotoxicity with alcoholism or receiving total cumulative dose (≥1.5g); withhold or discontinue if occurs. Increased risk for serious infections (eg, bacterial, fungal, viral) including opportunistic infections; monitor during and after treatment; withhold or discontinue if occur. Folate deficiency. Ascites, pleural effusions: evacuate fluid, monitor for toxicity and reduce dose or discontinue if needed. Hepatic or renal impairment: monitor closely and reduce dose or discontinue as appropriate. Update immunizations according to current guidelines prior to initiation. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Be fully familiar with this drug's toxicity before use. Obtain baseline and periodically monitor CBCs with differential, platelet counts, chest X-ray, and hepatic, renal and pulmonary function. Permanently discontinue if anaphylaxis or other severe hypersensitivity, or severe dermatologic reactions occur. Discontinue if lymphoproliferative disease occurs. Withhold, reduce dose, or discontinue if myelosuppression occurs. Withhold or discontinue if severe gastrointestinal toxicity, pulmonary toxicity, severe renal toxicity, or neurotoxicity occur. Peptic ulcer disease. Ulcerative colitis. Increased risk for hepatotoxicity with alcoholism or receiving total cumulative dose (≥1.5g); withhold or discontinue if occurs. Increased risk for serious infections (eg, bacterial, fungal, viral) including opportunistic infections; monitor during and after treatment; withhold or discontinue if occur. Folate deficiency. Ascites, pleural effusions: evacuate fluid, monitor for toxicity and reduce dose or discontinue if needed. Hepatic or renal impairment: monitor closely and reduce dose or discontinue as appropriate. Update immunizations according to current guidelines prior to initiation. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).